Chinese Journal of Antituberculosis ›› 2026, Vol. 48 ›› Issue (7): 1051-1063.doi: 10.19982/j.issn.1000-6621.20260030
• Original Articles • Previous Articles Next Articles
Yin Shiliu1, Xu Dan2, Li Zheng2, Wang Yanqian3, Li Fengsen3(
)
Received:2026-01-16
Online:2026-07-10
Published:2026-07-02
Contact:
Li Fengsen, Email: Supported by:CLC Number:
Yin Shiliu, Xu Dan, Li Zheng, Wang Yanqian, Li Fengsen. Bibliometric analysis of research on post-tuberculosis sequelae (2006—2025): a preliminary exploration based on Web of Science[J]. Chinese Journal of Antituberculosis, 2026, 48(7): 1051-1063. doi: 10.19982/j.issn.1000-6621.20260030
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20260030
| 第一作者 | 标题 | 发表期刊 | 发表年份 | 总被引频次 |
|---|---|---|---|---|
| Ravimohan[ | Tuberculosis and lung damage: f-rom epidemiology to pathophysi-ology | European Respiratory Review | 2018 | 344 |
| Romanoski[ | Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis | Lancet Global Health | 2019 | 202 |
| Allwood[ | Post-tuberculosis lung health: perspectives from the First Internatonal Symposium | International Journal of Tuberculosis and Lung Disease | 2020 | 154 |
| Allwood[ | Post-Tuberculosis Lu-ng Disease: Clinical Review of an Under-Recognised Global Challenge | Respiration | 2021 | 151 |
| Menzies[ | Lifetime burden of disease due t-o incident tuberculosis: a global reappraisal including post-tuberculosis sequelae | Lancet Global Health | 2021 | 149 |
| Meghji[ | Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study | Thorax | 2021 | 128 |
| Migliori[ | Clinical standards f-or the assessment, management and rehabilitation of post-TB lung disease | International Journal of Tuberculosis and Lung Disease | 2021 | 127 |
| Dodd[ | Quantifying the global number of tuberculosis survivors: a modelling study | The Lancet Infectious Diseases | 2021 | 100 |
| Van Kampen[ | International research and guidelines on post-tuberculosis chronic lung disorders: a systematic sco-ping review | BMJ Global Health | 2018 | 92 |
| Nightingale[ | Post-TB health and wellbeing | International Journal of Tuberculosis and Lung Disease | 2023 | 79 |
| [1] | 屈燕, 李涛, 马文斌, 等. 世界卫生组织《2025年全球结核病报告》解读[J]. 结核与肺部疾病杂志, 2025, 6(6): 613-623. doi:10.19983/j.issn.2096-8493.20250178. |
| [2] |
Allwood B W, van der Zalm M M, Amaral A F S, et al. Post-tuberculosis lung health: perspectives from the First International Symposium[J]. Int J Tuberc Lung Dis, 2020, 24(8): 820-828. doi:10.5588/ijtld.20.0067.
pmid: 32912387 |
| [3] |
Allwood B W, Nightingale R, Agbota G, et al. Perspectives from the 2nd International Post-Tuberculosis Symposium: mobilising advocacy and research for improved outcomes[J]. IJTLD Open, 2024, 1(3): 111-123. doi:10.5588/ijtldopen.23.0619.
pmid: 38966406 |
| [4] | Ravimohan S, Kornfeld H, Weissman D, et al. Tuberculosis and lung damage: from epidemiology to pathophysiology[J]. Eur Respir Rev, 2018, 27(147): 170077. doi:10.1183/16000617.0077-2017. |
| [5] |
Meghji J, Lesosky M, Joekes E, et al. Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study[J]. Thorax, 2020, 75(3): 269-278. doi:10.1136/thoraxjnl-2019-213808.
pmid: 32102951 |
| [6] | Xing Z, Sun T, Janssens J P, et al. Airflow obstruction and small airway dysfunction following pulmonary tuberculosis: a cross-sectional survey[J]. Thorax, 2023, 78(3): 274-280. doi:10.1136/thoraxjnl-2021-218345. |
| [7] | Woldesemayat E M, Vera J H, Tanner C, et al. Lung function of tuberculosis patients after completion of treatment in Sidama, South Ethiopia[J]. Front Med (Lausanne), 2025, 12: 1451861. doi:10.3389/fmed.2025.1451861. |
| [8] | Basham C A, Karim M E, Cook V J, et al. Post-tuberculosis airway disease: A population-based cohort study of people immigrating to British Columbia, Canada, 1985—2015[J]. EClinicalMedicine, 2021, 33: 100752. doi:10.1016/j.eclinm.2021.100752. |
| [9] |
Chin A T, Rylance J, Makumbirofa S, et al. Chronic lung disease in adult recurrent tuberculosis survivors in Zimbabwe: a cohort study[J]. Int J Tuberc Lung Dis, 2019, 23(2): 203-211. doi:10.5588/ijtld.18.0313.
pmid: 30808453 |
| [10] | Gai X, Allwood B, Sun Y. Post-tuberculosis lung disease and chronic obstructive pulmonary disease[J]. Chin Med J (Engl), 2023, 136(16): 1923-1928. doi:10.1097/CM9.0000000000002771. |
| [11] | Joo D H, Kim M C, Sin S, et al. Incidence and Risk Factors of Tuberculosis-Associated Chronic Obstructive Pulmonary Disease[J]. Int J Chron Obstruct Pulmon Dis, 2025, 20: 2091-2102. doi:10.2147/COPD.S523732. |
| [12] | Choi H, Lee H, Ra S W, et al. Clinical Characteristics of Patients with Post-Tuberculosis Bronchiectasis: Findings from the KMBARC Registry[J]. J Clin Med, 2021, 10(19): 4542. doi:10.3390/jcm10194542. |
| [13] | Raj P A, Leach L A D, Davis C E. Chronic Lung Damage After Tuberculosis: A Focus on Bronchiectasis and Its Management[J]. Am J Respir Crit Care Med, 2025, 211: A2049. doi:10.1164/ajrccm.2025.211.Abstracts.A2409. |
| [14] |
Liu T, Gao L, Xie S, et al. Clinical and imaging spectrum of tuberculosis-associated fibrosing mediastinitis[J]. Clin Respir J, 2018, 12(5): 1974-1980. doi:10.1111/crj.12766.
pmid: 29356415 |
| [15] | Louw E H, van Heerden J A, Kalla I S, et al. Scoping review of post-TB pulmonary vascular disease: Proceedings from the 2nd International Post-Tuberculosis Symposium[J]. Pulm Circ, 2024, 14(3): e12424. doi:10.1002/pul2.12424. |
| [16] | Louw E, Baines N, Maarman G, et al. The prevalence of pulmonary hypertension after successful tuberculosis treatment in a community sample of adult patients[J]. Pulm Circ, 2023, 13(1): e12184. doi:10.1002/pul2.12184. |
| [17] | Hanalla M, Mohamed M A, Virnig S, et al. Post-tuberculosis Destroyed Lung Syndrome: A Case Report and Review of Management Challenges[J]. Am J Respir Crit Care Med, 2025, 211: A2376. doi:10.1164/ajrccm.2025.211.Abstracts.A2376. |
| [18] | Wu C Y, Hu H Y, Pu C Y, et al. Pulmonary tuberculosis increases the risk of lung cancer: a population-based cohort study[J]. Cancer, 2011, 117(3): 618-24. doi:10.1002/cncr.25616. |
| [19] |
Simonsen D F, Farkas D K, Søgaard M, et al. Tuberculosis and risk of cancer: a Danish nationwide cohort study[J]. Int J Tuberc Lung Dis, 2014, 18(10): 1211-1219. doi:10.5588/ijtld.14.0161.
pmid: 25216835 |
| [20] | Wu M, Yang Y N, Wang F, et al. Development of a Predictive Risk Model for Recurrence of Chronic Pulmonary Aspergillosis in Post-Tuberculosis Patients: A Retrospective Observational Study[J]. Int J Gen Med, 2025, 18: 7243-7254. doi:10.2147/IJGM.S544265. |
| [21] | Soundappan K, Singh Sehgal I, Prabhakar N, et al. Incidence and prevalence of chronic pulmonary aspergillosis in patients with post-tuberculosis lung abnormality: Results from a community survey in North India[J]. Mycoses, 2024, 67(3): e13711. doi:10.1111/myc.13711. |
| [22] | Rozaliyani A, Setianingrum F, Isbaniah F, et al. A Silent Threat in Post-Tuberculosis Patients: Chronic Pulmonary Aspergillosis Survey in Multiple Regions of Indonesia (I-CHROME Study)[J]. J Fungi (Basel), 2025, 11(5): 329. doi:10.3390/jof11050329. |
| [23] | Purwono A, Fachrucha F, Agustin H, et al. Chronic Pulmonary Aspergillosis in Patient With Post-Tuberculosis Treatment and Recurrent Hemoptysis[J]. Am J Respir Crit Care Med, 2023, 207: A5571. |
| [24] | Yang J, Kim S H, Sim J K, et al. Tuberculosis survivors and the risk of cardiovascular disease: analysis using a nationwide survey in Korea[J]. Front Cardiovasc Med, 2024, 11: 1364337. doi:10.3389/fcvm.2024.1364337. |
| [25] | Mendoza-Torres J, Durán-Hernández N, Choreño-Parra J, et al. Hippocampal syndrome secondary to tuberculosis: From neuroinflammation to neurodegeneration[J]. Tuberculosis (Edinb), 2025, 153: 102653. doi:10.1016/j.tube.2025.102653. |
| [26] | Lo H Y, Suo J, Chang H J, et al. Risk factors associated with death in a 12-month cohort analysis of tuberculosis patients: 12-month follow-up after registration[J]. Asia Pac J Public Health, 2015, 27(2): NP758-68. doi:10.1177/1010539511429591. |
| [27] | Kim S, Pelissari D M, Harada L O, et al. Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil[J]. Clin Infect Dis, 2026, 82(1): e1-e8. doi:10.1093/cid/ciaf206. |
| [28] | 秦丽莉, 杨澄清, 麦洪珍, 等. 结核后肺曲霉病的临床诊疗研究进展[J]. 中国防痨杂志, 2025, 47(4): 498-504. doi:10.19982/j.issn.1000-6621.20240527. |
| [29] | 宋菲尔, 毛燕君, 夏秋月, 等. 结核后肺疾病患者患病率和影响因素的Meta分析[J]. 中国防痨杂志, 2025, 47(3): 322-330. doi:10.19982/j.issn.1000-6621.20240454. |
| [30] |
Romanowski K, Baumann B, Basham C A, et al. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis[J]. Lancet Infect Dis, 2019, 19(10): 1129-1137. doi:10.1016/S1473-3099(19)30309-3.
pmid: 31324519 |
| [31] | Allwood BW, Byrne A, Meghji J, et al. Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge[J]. Respiration, 2021, 100(8): 751-763. doi:10.1159/000512531. |
| [32] |
Menzies N A, Quaife M, Allwood B W, et al. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae[J]. Lancet Glob Health, 2021, 9(12): e1679-e1687. doi:10.1016/S2214-109X(21)00367-3.
pmid: 34798027 |
| [33] |
Migliori G B, Marx F M, Ambrosino N, et al. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease[J]. Int J Tuberc Lung Dis, 2021, 25(10): 797-813. doi:10.5588/ijtld.21.0425.
pmid: 34615577 |
| [34] |
Dodd P J, Yuen C M, Jayasooriya S M, et al. Quantifying the global number of tuberculosis survivors: a modelling study[J]. Lancet Infect Dis, 2021, 21(7): 984-992. doi:10.1016/S1473-3099(20)30919-1.
pmid: 33640076 |
| [35] | van Kampen S C, Wanner A, Edwards M, et al. International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review[J]. BMJ Glob Health, 2018, 3(4): e000745. doi:10.1136/bmjgh-2018-000745. |
| [36] |
Nightingale R, Carlin F, Meghji J, et al. Post-TB health and wellbeing[J]. Int J Tuberc Lung Dis, 2023, 27(4): 248-283. doi:10.5588/ijtld.22.0514.
pmid: 37035971 |
| [37] |
Mpagama S G, Msaji K S, Kaswaga O, et al. The burden and determinants of post-TB lung disease[J]. Int J Tuberc Lung Dis, 2021, 25(10): 846-853. doi:10.5588/ijtld.21.0278.
pmid: 34615582 |
| [38] |
Thomson H, Baines N, Huisamen T, et al. A new understanding of clinical patterns in post-TB lung disease[J]. Int J Tuberc Lung Dis, 2024, 28(3): 115-121. doi:10.5588/ijtld.23.0327.
pmid: 38454184 |
| [39] | Webber T, Macdonald C, Tameris M, et al. Immune, metabolic, anatomical, and functional features of people after successful tuberculosis treatment: an exploratory analysis[J]. Sci Rep, 2025, 15(1): 18392. doi:10.1038/s41598-025-01656-1. |
| [40] | Wang L L, Lu H W, Li L L, et al. Destroyed lung contributes to the recurrence of hemoptysis after bronchial artery embolization in patients with post-tuberculosis bronchiectasis[J]. J Infect Public Health, 2024, 17(7): 102446. doi:10.1016/j.jiph.2024.05.003. |
| [41] | Auld S C, Barczak A K, Bishai W, et al. Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and Research Priorities at the Second International Post-Tuberculosis Symposium[J]. Am J Respir Crit Care Med, 2024, 210(8): 979-993. doi:10.1164/rccm.202402-0374SO. |
| [42] | Santos A P, Rodrigues L S, Rother N, et al. The role of neutrophil response in lung damage and post-tuberculosis lung disease: a translational narrative review[J]. Front Immunol, 2025, 16: 1528074. doi:10.3389/fimmu.2025.1528074. |
| [1] | Zhou Wenxian, Qin Yamei, Yang Xuan, Zhao Na, Wu Kunli, He Qilian. A qualitative study on symptom cluster experience and management needs of patients with post-tuberculosis lung disease [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 1015-1020. |
| [2] | Gao Xian, Shang Xiyu, Liu Tiantian, Yang Jie, Li Zixi, Sun Yange, Wei Jinsheng, Cheng Shiming, Ma Yan, Li Hongzhi. State-Target differentiation and treatment strategy for ulcerative lymph node tuberculosis with external application of Sanjie Plaster [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 1021-1029. |
| [3] | Liu Jia, Tan Jing, Tian Yao, Fu Manjiao, Liu Huimin, Chen Hongmei, Zhai An, Kang Yi, Chen Liang, Bei Chengli. Risk factors and predictive model for poor prognosis among HIV-negative patients with disseminated tuberculosis admitted to intensive care unit [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 933-940. |
| [4] | Ye Juexian, Zhou Qiankun, Li Donglan, Qin Xiongzhi, Fan Aimin, Liu Aimei. Construction of a clinical comprehensive evaluation system for anti-tuberculosis drugs based on Delphi and analytic hierarchy process [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 948-957. |
| [5] | Zhao Liping, Zong Xingyu, Cao Yuqing, Jiang Hui, Cai Qiujie, Ma Yan, Mu Tingting, Liu Xiaoming, Liu Bin, Liang Bowen, Cao Yanhua, Li Bo, Luo Jingyue, Wang Guirong, Huang Mailing. Adjuvant therapy with Zhonghe Decoction for abscess lymph node tuberculosis with Qi and blood deficiency syndrome: a randomized controlled trial on short-term efficacy [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 1044-1050. |
| [6] | Chinese Antituberculosis Association, Nutrition Branch of the Chinese Antituberculosis Association, Hunan Antituberculosis Association, Hunan Institute for Tuberculosis Control (Hunan Chest Hospital), Shanghai Pulmonary Hospital, Xiangya School of Public Health, Central South University. Expert consensus on nutritional therapy for tuberculosis and diabetes mellitus comorbidity [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 913-924. |
| [7] | Chen Yina, Li Weidan, Zhu Kaiqiang, Tang Huiling. Serfling regression model for analyzing tuberculosis epidemiological characteristics in Jinhua City,Zhejiang Province [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 941-947. |
| [8] | Liu Liangli, Yang Yunbin, Yang Rui, Chen Jinou, Yang Xing, Qiu Yubing, Li Ling, Xu Lin. Temporal trends and influencing factors of adverse treatment outcomes in patients with rifampicin-resistant pulmonary tuberculosis: a comparison based on different treatment regimens [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 958-964. |
| [9] | Wei Xiaowen, Dong Ning, Wu Yuanhao, Yang Jie, Yang Yijing, Shen Kelan, Zhang Lin. Effects of intervention scheme based on the theory of goal attainment on discharge readiness of patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 1007-1014. |
| [10] | Yang Tao, Song Yanhong, Shi Xiaoying, Zheng Yuanhang, Qian Kai, Li Jing, Luo Yi. Clinical research progress on isoniazid combined with rifapentine regimen in Chinese population with latent tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 1064-1068. |
| [11] | Zeng Yi, Gao Weiwei, Shi Cuilin, Su Shifang, Wang Hua, Tang Jun, Shi Jichan, Nie Qi, Sun Yan, Cui Junwei, Yang Junjun, Fan Jiahua. Effectiveness and safety of Yujieli as a nutritional supplement in newly diagnosed, nutritionally deficient patients with rifampicin-sensitive active pulmonary tuberculosis: a multicenter, randomized, controlled clinical trial [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 925-932. |
| [12] | Jiao Xiaoke, Dong Kexin, Yang Xinliang, Nie Wenjuan. Risk factors for QTc interval >500 ms in patients with rifampicin-resistant tuberculosis treated with bedaquiline-containing regimens [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 992-999. |
| [13] | Liu Aimei, Liu Sang, Feng Lizhen, Wang Qing. Evaluation of surgical outcomes in tuberculosis complicated with HIV/AIDS based on CD4+ T lymphocyte levels [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 1000-1006. |
| [14] | Feng Yinping, Luo Shuirong, Liu Zhongda, Zhang Zunjing. An association study of the comorbidity spectrum and core traditional Chinese medicine syndromes in 832 elderly patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 1038-1043. |
| [15] | You Jicun, Tian Lei, Wang Lingyan, Yang Zhongrong, Shen Jianyong, Chen Bin. Analysis of latent tuberculosis infection prevalence and its related factors in 1007 patients with diabetes mellitus [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 965-971. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.